COMP <GO>
QGEN vs KRYS // FORWARD P/E MULTIPLE
Qiagen N.V. (NYSE) VS. Krystal Biotech Inc. (NASDAQ) • 15-METRIC TALLY: QGEN 8
— KRYS 5
▲ FORWARD P/E MULTIPLE LEADER: QGEN
LAST: $50.34 (+0.02%) • MKT CAP: $10.37B
forward-pe
22.7x
LAST: $324.55 (+0.97%) • MKT CAP: $9.61B
forward-pe
39.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QGEN VS. KRYS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QGEN | KRYS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.00% | 16.50% | -8.50 | KRYS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 53.4x | -35.80 | QGEN | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 1.97% | +2.40 | QGEN | /fcf-yield <GO> |
| Operating Margin | 22.30% | 41.50% | -19.20 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 20.30% | 52.60% | -32.30 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 33.90% | -28.20 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.52% | 0.00% | +0.52 | QGEN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 26.00 | -22.46 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | QGEN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 72.4 | 48.2 | +24.20 | QGEN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.91 | +0.04 | QGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 22.7x | 39.4x | -16.70 | QGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.37B | $9.61B | $767.5M | QGEN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QGEN REV | KRYS REV | QGEN GROSS % | KRYS GROSS % | QGEN FCF | KRYS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.09B | $389.1M | 62.2% | — | $453.3M | $188.9M |
| FY 2024 | $1.98B | $290.5M | 48.9% | — | $506.4M | $119.2M |
| FY 2023 | $1.97B | $50.7M | — | — | $371.0M | -$91.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QGEN // BETA 0.95
KRYS // BETA 0.91